Cargando…

Engineering anti-cancer nanovaccine based on antigen cross-presentation

Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules, thereby activating CD8(+) T cells, contributing to tumor elimination through a mechanism known as antigen cross-presentation. A variety of factors such as maturation state of DCs, co-stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Warrier, Vaishnavi U., Makandar, Amina I., Garg, Manoj, Sethi, Gautam, Kant, Ravi, Pal, Jayanta K., Yuba, Eiji, Gupta, Rajesh Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822533/
https://www.ncbi.nlm.nih.gov/pubmed/31652460
http://dx.doi.org/10.1042/BSR20193220
_version_ 1783464360057765888
author Warrier, Vaishnavi U.
Makandar, Amina I.
Garg, Manoj
Sethi, Gautam
Kant, Ravi
Pal, Jayanta K.
Yuba, Eiji
Gupta, Rajesh Kumar
author_facet Warrier, Vaishnavi U.
Makandar, Amina I.
Garg, Manoj
Sethi, Gautam
Kant, Ravi
Pal, Jayanta K.
Yuba, Eiji
Gupta, Rajesh Kumar
author_sort Warrier, Vaishnavi U.
collection PubMed
description Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules, thereby activating CD8(+) T cells, contributing to tumor elimination through a mechanism known as antigen cross-presentation. A variety of factors such as maturation state of DCs, co-stimulatory signals, T-cell microenvironment, antigen internalization routes and adjuvants regulate the process of DC-mediated antigen cross-presentation. Recently, the development of successful cancer immunotherapies may be attributed to the ability of DCs to cross-present tumor antigens. In this review article, we focus on the underlying mechanism of antigen cross-presentation and ways to improve antigen cross-presentation in different DC subsets. We have critically summarized the recent developments in the generation of novel nanovaccines for robust CD8(+) T-cell response in cancer. In this context, we have reviewed nanocarriers that have been used for cancer immunotherapeutics based on antigen cross-presentation mechanism. Additionally, we have also expressed our views on the future applications of this mechanism in curing cancer.
format Online
Article
Text
id pubmed-6822533
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-68225332019-11-06 Engineering anti-cancer nanovaccine based on antigen cross-presentation Warrier, Vaishnavi U. Makandar, Amina I. Garg, Manoj Sethi, Gautam Kant, Ravi Pal, Jayanta K. Yuba, Eiji Gupta, Rajesh Kumar Biosci Rep Cancer Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules, thereby activating CD8(+) T cells, contributing to tumor elimination through a mechanism known as antigen cross-presentation. A variety of factors such as maturation state of DCs, co-stimulatory signals, T-cell microenvironment, antigen internalization routes and adjuvants regulate the process of DC-mediated antigen cross-presentation. Recently, the development of successful cancer immunotherapies may be attributed to the ability of DCs to cross-present tumor antigens. In this review article, we focus on the underlying mechanism of antigen cross-presentation and ways to improve antigen cross-presentation in different DC subsets. We have critically summarized the recent developments in the generation of novel nanovaccines for robust CD8(+) T-cell response in cancer. In this context, we have reviewed nanocarriers that have been used for cancer immunotherapeutics based on antigen cross-presentation mechanism. Additionally, we have also expressed our views on the future applications of this mechanism in curing cancer. Portland Press Ltd. 2019-10-18 /pmc/articles/PMC6822533/ /pubmed/31652460 http://dx.doi.org/10.1042/BSR20193220 Text en © 2019 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
spellingShingle Cancer
Warrier, Vaishnavi U.
Makandar, Amina I.
Garg, Manoj
Sethi, Gautam
Kant, Ravi
Pal, Jayanta K.
Yuba, Eiji
Gupta, Rajesh Kumar
Engineering anti-cancer nanovaccine based on antigen cross-presentation
title Engineering anti-cancer nanovaccine based on antigen cross-presentation
title_full Engineering anti-cancer nanovaccine based on antigen cross-presentation
title_fullStr Engineering anti-cancer nanovaccine based on antigen cross-presentation
title_full_unstemmed Engineering anti-cancer nanovaccine based on antigen cross-presentation
title_short Engineering anti-cancer nanovaccine based on antigen cross-presentation
title_sort engineering anti-cancer nanovaccine based on antigen cross-presentation
topic Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822533/
https://www.ncbi.nlm.nih.gov/pubmed/31652460
http://dx.doi.org/10.1042/BSR20193220
work_keys_str_mv AT warriervaishnaviu engineeringanticancernanovaccinebasedonantigencrosspresentation
AT makandaraminai engineeringanticancernanovaccinebasedonantigencrosspresentation
AT gargmanoj engineeringanticancernanovaccinebasedonantigencrosspresentation
AT sethigautam engineeringanticancernanovaccinebasedonantigencrosspresentation
AT kantravi engineeringanticancernanovaccinebasedonantigencrosspresentation
AT paljayantak engineeringanticancernanovaccinebasedonantigencrosspresentation
AT yubaeiji engineeringanticancernanovaccinebasedonantigencrosspresentation
AT guptarajeshkumar engineeringanticancernanovaccinebasedonantigencrosspresentation